Valve Thrombosis After TAVR: Larger-Diameter Valves and No Warfarin as Predictors

Valve Thrombosis After TAVRThere are limited data on the incidence, clinical implications, and predisposing factors of valve thrombosis in patients who underwent transcatheter aortic valve replacement (TAVR). This study aimed at determining such information through multislice computed tomography (CT).

 

This trial included 460 consecutive patients who underwent TAVR with a balloon-expandable Edwards Sapien XT or Sapien 3 (Edwards Lifesciences, Irvine, California) device.

 

Of those, 405 patients were assessed through multislice CT in addition to transthoracic or transesophageal echocardiography 1 to 3 months after TAVR. CT scans were evaluated for hypodense thickening matching valve thrombosis.

 

The CT confirmed signs of valve thrombosis in 28 patients (7%), 23 of which were completely asymptomatic. The remaining 5 patients presented symptoms indicating obstructive valve thrombosis.

 

Valve thrombosis risk did not differ among different generations of devices, but it was more frequent in patients who did not receive warfarin when compared with anticoagulated patients (10.7% vs. 1.8%; risk ratio [RR]: 6.09; 95% confidence interval [CI]: 1.86 to 19.84). Larger-diameter valves were associated with an increased risk of thrombosis (p = 0.03).

 

In a multivariable analysis, 29-mm devices (RR: 2.89; 95% CI: 1.44 to 5.80) and no post-TAVR warfarin treatment (RR: 5.46; 95% CI: 1.68 to 17.7) were independent predictors of thrombosis.

 

Treatment with warfarin effectively reverted valve thrombosis in 85% of patients, as shown by follow-up transesophageal echocardiography and multislice computed tomography.

 

Conclusion

Incidence of valve thrombosis after transcatheter aortic valve replacement in this study was 7%. Larger-diameter valves showed higher predisposition to thrombosis, whereas warfarin treatment had a protective effect. Although most patients did not present symptoms, the clinical implications of valve thrombosis may be important.

 

Original title: Transcatheter Aortic Valve Thrombosis Incidence, Predisposing Factors, and Clinical Implications.

Reference: Nicolaj C. Hansson et al. J Am Coll Cardiol. 2016;68(19):2059-2069.

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...